证券日报网讯特宝生物11月25日在互动平台回答投资者提问时表示，截至2025年9月30日，公司股东人 数为8608户。 （文章来源：证券日报） ...

Market Overview - The biopharmaceutical sector increased by 0.83% on November 25, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Biopharmaceutical Sector - Jinke (688670) closed at 25.75, up 19.99% with a trading volume of 92,200 shares [1] - Hualan Biological (301207) closed at 23.33, up 11.25% with a trading volume of 250,500 shares [1] - Saiseng Pharmaceutical (300485) closed at 11.95, up 5.19% with a trading volume of 168,000 shares [1] - Other notable gainers include Bohui Innovation (300318) at 6.84 (+3.32%) and Dongbao Biological (300239) at 5.72 (+3.25%) [1] Market Capital Flow - The biopharmaceutical sector saw a net inflow of 40.88 million yuan from institutional investors, while retail investors experienced a net outflow of 147 million yuan [2] - The sector's overall capital flow indicates a strong interest from institutional investors despite retail selling pressure [2] Individual Stock Capital Flow - Jinke (688670) had a net inflow of 39.66 million yuan from institutional investors, while retail investors showed a net outflow of 13.72 million yuan [3] - Other stocks like Watson Bio (300142) and Hualan Bio (002007) also experienced significant net inflows from institutional investors, indicating positive sentiment [3] - Conversely, stocks like Dongbao Biological (300239) and Bohui Innovation (300318) faced net outflows from retail investors, suggesting mixed investor sentiment [3]

Core Viewpoint - The company primarily focuses on domestic sales, with a small proportion of overseas sales revenue, and does not export to EU countries [2] Group 1 - The company's main business products are primarily sold domestically [2] - The proportion of overseas sales revenue is relatively small [2] - The countries to which the company exports do not include those in the European Union [2]

Core Insights - The company primarily focuses on domestic sales, with overseas sales accounting for a small proportion of total revenue, and it does not export to EU countries [1]. Group 1 - The company's main business products are primarily sold domestically [1]. - The proportion of overseas sales revenue is relatively small [1]. - The company does not export to EU countries [1].

Core Viewpoint - The company primarily focuses on domestic sales, with a small proportion of overseas sales revenue, and does not export to EU countries [1] Group 1 - The main business products of the company are primarily sold domestically [1] - The overseas sales revenue constitutes a minor part of the overall revenue [1] - The countries to which the company exports do not include any EU member states [1]

Core Viewpoint - The company primarily focuses on domestic sales, with a small proportion of overseas sales revenue, and does not export to EU countries [1] Group 1 - The main business products of the company are primarily for domestic sales [1] - The overseas sales revenue constitutes a small percentage of the total revenue [1] - The countries to which the company exports do not include any EU member states [1]

Core Insights - The biopharmaceutical sector experienced a decline of 0.98% on November 18, with He Yuan Bio leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance Summary - Notable gainers included: - Aopu Mai (688293) with a closing price of 58.80, up 3.38% on a trading volume of 15,900 shares and a transaction value of 93.39 million [1] - Jin Hu Ke (688670) at 26.80, up 2.88% with a volume of 116,300 shares and a transaction value of 319 million [1] - Te Bao Bio (688278) at 77.08, up 1.22% with a volume of 10,800 shares and a transaction value of 82.57 million [1] - Notable decliners included: - Bu Yuan Bio (688765) at 79.95, down 3.89% with a volume of 56,800 shares and a transaction value of 458 million [2] - San Sheng Guo Jian (688336) at 67.60, down 3.87% with a volume of 68,100 shares and a transaction value of 469 million [2] - Wo Wu Bio (300357) at 31.77, down 3.23% with a volume of 77,900 shares and a transaction value of 250 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 981 million from institutional investors, while retail investors contributed a net inflow of 819 million [2] - Key stocks with significant capital flow included: - Hua Lan Vaccine (301207) with a net inflow of 48.51 million from institutional investors [3] - Rong Chang Bio (688331) with a net inflow of 23.62 million from institutional investors [3] - Jin Ke (688670) with a net inflow of 5.53 million from institutional investors [3]

Group 1 - The company, TeBao Bio, announced that it will hold the 14th meeting of the 9th Board of Directors on November 17, 2025, to review the proposal for external donations [2]

Core Viewpoint - The company is committed to supporting children with growth hormone deficiency through a charitable initiative, addressing both health and economic challenges faced by affected families [1] Group 1: Company Initiatives - The company has developed a national class 1 new drug, Yipeisheng (怡培生长激素注射液), for treating growth hormone deficiency in children aged 3 and above [1] - The company has decided to donate up to 40,000 doses of Yipeisheng and up to 661,600 RMB in cash to the Beijing Hongxin Xiangtong Charity Foundation to support the "Yilu Xiangban" patient assistance project [1] Group 2: Industry Context - Growth hormone deficiency in children can lead to various issues, including reduced height, lower quality of life, and potential behavioral, cognitive, and psychological disorders [1] - The initiative aligns with the "Healthy China 2030" planning outline, aiming to provide continuous and standardized treatment for more children in need [1]

厦门特宝生物工程股份有限公司 章程 2025 年 11 月 | 第一章 | 总则 | | 3 | | --- | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 4 | | | 第三章 | 股份 | | 4 | | 第一节 | 股份发行 | 4 | | | 第二节 | 股份增减和回购 | 5 | | | 第三节 | 股份转让 | 6 | | | 第四章 | 股东和股东大会 | 7 | | | 第一节 | 股东 | | 7 | | 第二节 | 股东大会的一般规定 | 9 | | | 第三节 | 股东大会的召集 | 14 | | | 第四节 | 股东大会的提案与通知 | | 15 | | 第五节 | 股东大会的召开 | 16 | | | 第六节 | 股东大会的表决和决议 | | 19 | | 第五章 | 董事会 | 24 | | | 第一节 | 董事 | 24 | | | 第二节 | 董事会 | 27 | | | 第六章 | 总经理及其他高级管理人员 | 32 | | | 第七章 | 监事会 | 34 | | | 第一节 | 监事 | 34 | | | 第二节 | 监事会 | 35 | | ...